Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
2.51 ^USD	-1.18%		-15.20%	-23.12%

04-24	Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	CI
04-08	Gain Therapeutics Names Gene Mack as CFO	MT

Gain Therapeutics, Inc. Announces the Resignation of C. Evan Ballantyne as Chief Financial Officer, Effective March 1, 2024

February 22, 2024 at 07:00 am

On February 19, 2024, Gain Therapeutics, Inc. received notice of the resignation of C. Evan Ballantyne as the Company's Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.

Latest news about Gain Therapeutics, Inc.

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	04-24	CI
Gain Therapeutics Names Gene Mack as CFO	04-08	MT
Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer	04-08	CI
Gain Therapeutics Names Chief Medical Officer	04-01	MT
Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer	04-01	CI
Gain Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Gain Therapeutics, Inc. Appoints Gianluca Fuggetta as the Vice President of Finance and Principal Financial Officer from Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, Effective March 1, 2024	02-22	CI
Gain Therapeutics, Inc. Announces the Resignation of C. Evan Ballantyne as Chief Financial Officer, Effective March 1, 2024	02-22	CI
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.	02-18	CI
Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer	01-31	CI
HC Wainwright Trims Price Target on Gain Therapeutics to $9 From $10, Keeps Buy Rating	12-04	MT
Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model	12-01	CI
Gain Therapeutics Closes $10.1 Million Public Offering, Private Placement of Shares, Warrants	11-24	MT
Gain Therapeutics, Inc. announced that it has received $5.000176 million in funding	11-23	CI
Top Premarket Decliners	11-21	MT
Gain Therapeutics Shares Tumble After Announcement of Public Offering	11-20	MT
Gain Therapeutics, Inc. announced that it expects to receive $5.000176 million in funding	11-19	CI
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson?s Disease	23-10-04	CI
Maxim Starts Gain Therapeutics at Buy With $10 Price Target	23-09-12	MT
Gain Therapeutics Says Data Shows GT-02287 Significantly Decreases Parkinson's Pathology	23-08-28	MT
Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model	23-08-28	CI
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Gain Therapeutics, Inc.(NasdaqGM:GANX) added to Russell 3000E Growth Index	23-06-23	CI
Gain Therapeutics, Inc.(NasdaqGM:GANX) dropped from Russell 3000E Value Index	23-06-23	CI

Chart Gain Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Companyâs drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinsonâs disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Gain Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.51 USD

Average target price

8.8 USD

Spread / Average Target

+250.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GAIN THERAPEUTICS, INC.	-23.12%	45.31M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+46.45%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research